Movement Alert｜Axsome Therapeutics Rises 5.01% in Regular Trading, Q2 Revenue Up 46% YoY as Stock Recovers Pre-Market Losses

Market Focus08-11

On August 10, Axsome Therapeutics rose 5.01% in regular trading, trading at $223.4/share, with turnover of $200 million. The stock had fallen over 8% in pre-market trading after reporting Q2 results that missed consensus estimates, but swiftly recovered during the regular session.

The company reported Q2 GAAP loss of $0.99 per share, missing the analyst consensus estimate of $0.83-$0.89. Revenue came in at $218.4 million, falling short of the $221.1 million estimate by approximately $3.4 million. However, investors appeared to refocus on the strong underlying growth trajectory: total net product revenue grew 46% year-over-year, with flagship product AUVELITY generating $180.3 million in net sales, representing 51% year-over-year growth. The robust commercial momentum of the core CNS portfolio, combined with pipeline catalysts including FDA acceptance of the AXS-12 NDA for cataplexy in narcolepsy with a May 2027 PDUFA date, helped drive the intraday reversal.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117614375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117614375","market":"us","top_or_hot":-1,"title":"Movement Alert｜Axsome Therapeutics Rises 5.01% in Regular Trading, Q2 Revenue Up 46% YoY as Stock Recovers Pre-Market Losses","media":"Market Focus","content":"<p><p>On August 10, Axsome Therapeutics rose 5.01% in regular trading, trading at $223.4/share, with turnover of $200 million. The stock had fallen over 8% in pre-market trading after reporting Q2 results that missed consensus estimates, but swiftly recovered during the regular session.</p><p>The company reported Q2 GAAP loss of $0.99 per share, missing the analyst consensus estimate of $0.83-$0.89. Revenue came in at $218.4 million, falling short of the $221.1 million estimate by approximately $3.4 million. However, investors appeared to refocus on the strong underlying growth trajectory: total net product revenue grew 46% year-over-year, with flagship product AUVELITY generating $180.3 million in net sales, representing 51% year-over-year growth. The robust commercial momentum of the core CNS portfolio, combined with pipeline catalysts including FDA acceptance of the AXS-12 NDA for cataplexy in narcolepsy with a May 2027 PDUFA date, helped drive the intraday reversal.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Axsome Therapeutics Rises 5.01% in Regular Trading, Q2 Revenue Up 46% YoY as Stock Recovers Pre-Market Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Axsome Therapeutics Rises 5.01% in Regular Trading, Q2 Revenue Up 46% YoY as Stock Recovers Pre-Market Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 02:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, Axsome Therapeutics rose 5.01% in regular trading, trading at $223.4/share, with turnover of $200 million. The stock had fallen over 8% in pre-market trading after reporting Q2 results that missed consensus estimates, but swiftly recovered during the regular session.</p><p>The company reported Q2 GAAP loss of $0.99 per share, missing the analyst consensus estimate of $0.83-$0.89. Revenue came in at $218.4 million, falling short of the $221.1 million estimate by approximately $3.4 million. However, investors appeared to refocus on the strong underlying growth trajectory: total net product revenue grew 46% year-over-year, with flagship product AUVELITY generating $180.3 million in net sales, representing 51% year-over-year growth. The robust commercial momentum of the core CNS portfolio, combined with pipeline catalysts including FDA acceptance of the AXS-12 NDA for cataplexy in narcolepsy with a May 2027 PDUFA date, helped drive the intraday reversal.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1117614375","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117614375","pubTimestamp":1786388371,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, Axsome Therapeutics rose 5.01% in regular trading, trading at $223.4/share, with turnover of $200 million. The stock had fallen over 8% in pre-market trading after reporting Q2 results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"走势提醒|Axsome Therapeutics 常规交易中上涨 5.01%，第二季度收入同比增长 46%，股票收复盘前损失","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1},"content_text":"On August 10, Axsome Therapeutics rose 5.01% in regular trading, trading at $223.4/share, with turnover of $200 million. The stock had fallen over 8% in pre-market trading after reporting Q2 results that missed consensus estimates, but swiftly recovered during the regular session.The company reported Q2 GAAP loss of $0.99 per share, missing the analyst consensus estimate of $0.83-$0.89. Revenue came in at $218.4 million, falling short of the $221.1 million estimate by approximately $3.4 million. However, investors appeared to refocus on the strong underlying growth trajectory: total net product revenue grew 46% year-over-year, with flagship product AUVELITY generating $180.3 million in net sales, representing 51% year-over-year growth. The robust commercial momentum of the core CNS portfolio, combined with pipeline catalysts including FDA acceptance of the AXS-12 NDA for cataplexy in narcolepsy with a May 2027 PDUFA date, helped drive the intraday reversal.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117614375","isCrawlerRequest":true}